Navigation Links
Mithridion raises $1.6M through angel networks

Madison, Wis. Mithridion, the University of Wisconsin-Madison spinoff developing a drug for people with Alzheimer's disease, has closed its first round of financing with $1.6 million, of which it has received the first portion, that will go toward buying lab equipment, hiring scientists and developing drug candidates.

Trevor Twose, Mithridion's ......

Full article >>> als are successful Mithridion will partner or sell to a large pharmaceutical company in stage two or three trials. By that time, its technology will be reasonably proven enough, at least, for a large pharma to take on the final testing and marketing.

Mithridion's product is based on research by Jeff Johnson,......

Full article >>>
'"/>

Source:wistechnology.com By Jason Stitt 02/01/06


Related biology technology :

1. Mithridion wins grants for Alzheimers research
2. Digital Healthcare Conference, Mithridion, lack of degrees
3. Madison-based Mithridion seeks to capitalize on Alzheimers breakthrough
4. TomoTherapy raises $223 million in IPO
5. Fusion 2007: CA chief says IT complexity raises risk
6. Inline intellectual property raises legal issues
7. Biotech with Madison ties raises $21M in capital
8. ConjuGon raises $3.3 million to fund clinical trials
9. Nerites raises $1 million to improve medical tech
10. Brady Corp. raises $137 million in public offering
11. aOva Technologies raises $3 million
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... to bring innovative medical technologies, services and solutions to the healthcare market. The ... implementation of various distribution, manufacturing, sales and marketing strategies that are necessary to ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:6/22/2016)... , June 22, 2016 On Monday, the ... to industry to share solutions for the Biometric Exit ... Customs and Border Protection (CBP), explains that CBP intends ... departing the United States , in ... to defeat imposters. Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/15/2016)... , June 15, 2016 ... report titled "Gesture Recognition Market by Application Market - Global Industry ... - 2024". According to the report, the  global gesture ... in 2015 and is estimated to grow at ... billion by 2024.  Increasing application of ...
(Date:6/3/2016)... LONDON , June 3, 2016 /PRNewswire/ ... Transport Management) von Nepal ... ,Angebot und Lieferung hochsicherer geprägter Kennzeichen, einschließlich ... weltweit führend in der Produktion und Implementierung ... an der Ausschreibung im Januar teilgenommen, aber ...
Breaking Biology News(10 mins):